So nice to see Alfredo Addeo MD Maxime Borgeaud from our oncology unit HUG Oncology Division - Geneva University Hospital presenting this international collaborative work on Uncommon EGFR mutations at #ELCC24 ESMO - Eur. Oncology 👏🙌

🔬🧵A deep dive into #NSCLC and the complex world of uncommon EGFR mutations! Our Timothée Olivier, MD Xiuning Le MD PhD Kaushal Parikh Maxime Borgeaud latest systematic review sheds light on the efficacy of TKIs across these lesser-known territories. Let's unravel the findings! [1/5] Full

Pleased to share our brand-new certification for our Lung Cancer Centre—a unique quality label within the Canton of Geneva. This achievement has been made possible thanks to an incredible team effort, unwavering commitment, and strong support HUG

just hot off the press, our Oncology Division - Geneva University Hospital HUG review "Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back". Congrats to all the co-authors , Maxime Borgeaud Dr Mariniello, Dr Kim, Dr Weiner, Dr Frisone. Here the

Activating mutations in EGFR gene has revolutionized management of #LungCancer, enabling development of TKIs. New review on strategies to optimize treatment: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… Alfredo Addeo MD Maxime Borgeaud Timothée Olivier, MD Jair Bar Kaushal Parikh Jill Feldman Xiuning Le MD PhD OncoAlert

Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… thanks to all the co-authors, great team

Fantastic work together with Alfredo Addeo MD Jill Feldman and my global colleagues. Now we have identified clinical and molecular poor prognostic factors, we just have to push forward to improve outcomes for those patients. MD Anderson Cancer Center Eric K. Singhi, MD OncoViews OncoDaily

Whatever you want to know about #EGFR-addicted lung cancer, from the very beginning to today, you’ll find it in this masterpiece. It’s been a real privilege to collaborate on this project. Maxime Borgeaud Timothée Olivier, MD Jair Bar Kaushal Parikh Jill Feldman Xiuning Le MD PhD Alfredo Addeo MD

A state-of-the-art Review on #EGFR mutant #NSCLC in the most prestigious journal in the world. A must-read for all thoracic oncologists! I enjoyed every single 📖 Congratulations Alfredo Addeo MD Xiuning Le MD PhD Stephanie Saw Giuseppe Banna and all co-authors, this will be the reference paper

Out in one of our partner Journals CA: A Cancer Journal for Clinicians Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management buff.ly/vv1ol7z The discovery of EGFR 🧬 mutations has transformed the treatment of

Mutations in the tyrosine kinase domain of EGFR represent one of the most common druggable alterations in #NSCLC. This recent review provides a comprehensive clinical overview of the management of patients with EGFR-mutant NSCLC. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… OncoAlert Alfredo Addeo MD

“The online BREAKING-ICE App© out in The Lancet Oncology !” Out today in Drug Dev Letter ! drugdevletter.com/p/the-online-b…

With the evolving landscape of EGFR-directed therapies, there is no longer a clear 1st-line choice in the metastatic setting for EGFR-mutant NSCLC. A new editorial from Lauren Antrim MD & Jyoti Malhotra of City of Hope explains more: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… OncoAlert Alfredo Addeo MD